Why ChemoCentryx Stock Skyrocketed Today
Investors are excited about the biotech's game-changing new drug.
Stay updated with breaking news from Vasculitis Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investors are excited about the biotech's game-changing new drug.
Three new guidelines released for treatment and management of systemic vasculitis The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis. Vasculitis is a group of about 20 rare diseases that have inflammation of blood vessels in common, which can restrict blood flow and damage vital organs. The three guidelines cover six forms of vasculitis, and a fourth guideline on Kawasaki disease will be released in the coming weeks. "Many rheumatologists may have limited experien...
Tocilizumab holds firm as steroid-sparing agent in giant cell arteritis Source: Warrington K. When should biologic agents be introduced in giant cell arteritis and for how long should they be given? Presented at: Biologic Therapies Summit IX; May 21-23, 2021 (virtual meeting). Disclosures: Warrington reported no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALER...
ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee (“Committee”) on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV). In the final part of the public meeting, the Committee voted on three questions presented by the FDA: The Committee vote split 9-9 on the first question, whether...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated ... ChemoCentryx, Inc.May 7, 2021 GMT SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee (“Committee”) on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV). In the final part of the public meeting,...